NASDAQ: MNOVMedicinova Inc Stock
$1.45+0.00 (+0%)
Updated Apr 17, 2025
MNOV Price
$1.45
Fair Value Price
N/A
Market Cap
$71.12M
52 Week Low
$1.12
52 Week High
$2.55
P/E
-6.3x
P/B
1.35x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$11M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MNOV Overview
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNOV's potential to beat the market
- MNOV doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNOV
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important MNOV news, forecast changes, insider trades & much more!
MNOV News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNOV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNOV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MNOV is good value based on its book value relative to its share price (1.35x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
MNOV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MNOV due diligence checks available for Premium users.
Valuation
MNOV fair value
Fair Value of MNOV stock based on Discounted Cash Flow (DCF)
Price
$1.45
Fair Value
$1.06
Overvalued by
37.38%
MNOV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MNOV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.3x
Industry
-177.72x
Market
27.98x
MNOV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.35x
Industry
4.05x
MNOV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MNOV's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.8M
Profit Margin
0%
MNOV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$55.9M
Liabilities
$3.4M
Debt to equity
0.06
MNOV's short-term assets ($41.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNOV's short-term assets ($41.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNOV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MNOV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$1.0
Financing
$0.0
MNOV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNOV vs Biotech Stocks
Medicinova Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.